Aerie Pharmaceuticals major shareholder 500,000 Shares of Stock (AERI)
Aerie Pharmaceuticals (NASDAQ:AERI) major shareholder Group Holdings (Sbs) Advis Tpg 500,000 shares of Aerie Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, July 9th. The was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
AERI has been the subject of a number of recent research reports. Analysts at Canaccord Genuity initiated coverage on shares of Aerie Pharmaceuticals in a research note on Thursday, July 3rd. They set a “buy” rating and a $40.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Aerie Pharmaceuticals from $27.00 to $36.00 in a research note on Thursday, June 26th. They now have an “outperform” rating on the stock. Finally, analysts at Needham & Company LLC raised their price target on shares of Aerie Pharmaceuticals from $26.00 to $37.00 in a research note on Thursday, June 26th. They now have a “buy” rating on the stock.
Aerie Pharmaceuticals (NASDAQ:AERI) traded up 2.16% during mid-day trading on Friday, hitting $25.97. 345,770 shares of the company’s stock traded hands. Aerie Pharmaceuticals has a 52 week low of $10.25 and a 52 week high of $29.71. The stock has a 50-day moving average of $20.2 and a 200-day moving average of $19.07. The company’s market cap is $608.7 million.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings data on Monday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. Analysts expect that Aerie Pharmaceuticals will post $-1.43 EPS for the current fiscal year.
Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.